The grades of five biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
This week, La Jolla Pharmaceutical Company (LJPC) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, LJPC also gets A’s. For more information, get Portfolio Grader’s complete analysis of LJPC stock.
This week, Idenix Pharmaceuticals, Inc. (IDIX) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Idenix Pharmaceuticals is a biopharmaceutical company that discovers and develops drugs for the treatment of human viral and other infectious diseases. For more information, get Portfolio Grader’s complete analysis of IDIX stock.
Incyte Corporation (INCY) earns a B this week, jumping up from last week’s grade of C. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.
Progenics Pharmaceuticals, Inc.’s (PGNX) ratings are looking better this week, moving up to a B from last week’s C. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of PGNX stock.
This is a strong week for Celladon Corporation (CLDN). The company’s rating climbs to A from the previous week’s B. For more information, get Portfolio Grader’s complete analysis of CLDN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.